102. Rubinstein-Taybi syndrome Disease details / Clinical trials / Drug dev / DR info
Clinical trials : 3 / Drugs : 5 - (DrugBank : 1) / Drug target genes : 7 - Drug target pathways : 17
Rubinstein-Taybi syndrome and other diseases between which drug repositioning (DR) might occur (Sakate and Kimura 2021) . Circle size: Number of drugs, Line breadth: Score (Drug repositionability)
| ID | Diseases (Sorted by score) | Score |
|---|---|---|
| 102 | Rubinstein-Taybi syndrome | - |
| 13 | Multiple sclerosis/Neuromyelitis optica | 7.000 |
| 6 | Parkinson disease | 7.000 |
| 34 | Neurofibromatosis | 7.000 |
| 65 | Primary immunodeficiency | 7.000 |
| 85 | Idiopathic interstitial pneumonia | 7.000 |
| 89 | Lymphangioleiomyomatosis | 7.000 |
| 127 | Frontotemporal lobar degeneration | 7.000 |
| 222 | Primary nephrotic syndrome | 7.000 |
| 256 | Muscle glycogenosis | 7.000 |
| 331 | Idiopathic multicentric castleman disease | 7.000 |
| 26 | HTLV-1-associated myelopathy | 7.000 |
| 90 | Retinitis pigmentosa | 7.000 |
| 5 | Progressive supranuclear palsy | 7.000 |
| 233 | Wolfram syndrome | 7.000 |
| 3 | Spinal muscular atrophy | 7.000 |
| 2 | Amyotrophic lateral sclerosis | 7.000 |
| 149 | Hemiconvulsion hemiplegia epilepsy syndrome | 1.588 |
| 215 | Tetralogy of Fallot | 1.571 |
| 58 | Hypertrophic cardiomyopathy | 1.393 |
| 86 | Pulmonary arterial hypertension | 1.337 |